指南与共识儿科与产科急症重症综合管理与镇静镇痛消化、代谢与肾脏急症

瑞士儿童SARS-CoV-2相关儿童多系统炎症综合征(PIMS-TS;儿童多系统炎症综合征,MIS-C)诊断与管理最佳实践推荐

Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland.
指南 / 共识 · Front Pediatr · 2021-05-26
一句话结论瑞士多学科专家组经改良Delphi流程达成26条推荐,按休克型、川崎病样型、未分化炎症型三种表型给出PIMS-TS诊治路径,强调证据有限、需定期更新并鼓励患儿参加试验。

该指南由瑞士儿科重症、免疫/风湿、感染、血液与心脏专家组成的多学科组制定,经文献回顾后由四个工作组起草推荐,再以改良Delphi流程达成共识,推荐须获>80%同意方可接受。最终就26条推荐达成一致,涵盖诊断方法、抗炎、抗感染与支持治疗及随访,并形成按表型(休克型、川崎病样型、未分化炎症型)指导治疗的管理算法。作者指出现有PIMS-TS文献仅限于回顾性或前瞻性观察性研究,推荐基于这些队列研究、其他儿童与成人炎症性疾病的间接证据及国际卫生机构指南,属基于当前知识的最佳实践,鉴于缺乏高级别证据,需定期更新推荐并鼓励患者参加试验。

要点

  • 推荐由瑞士儿科重症、免疫/风湿、感染、血液与心脏多学科组以改良Delphi流程制定,每条须>80%同意,最终达成26条推荐。
  • 管理算法按表型分层:PIMS-TS伴(a)休克、(b)川崎病样表现、(c)未分化炎症表现,据此指导治疗。
  • 推荐覆盖诊断方法、抗炎、抗感染与支持治疗及随访,适用于疑似PIMS-TS患儿。
  • 现有证据仅限于回顾性或前瞻性观察性研究,无高级别证据,推荐需定期更新。
  • 作者鼓励患者参加临床试验。

适用人群与场景

  • 疑似PIMS-TS的儿童(瑞士指南适用人群)。

处置流程与药物剂量

  • 按表型分层治疗:PIMS-TS伴(a)休克、(b)川崎病样表现、(c)未分化炎症表现,管理算法据此指导治疗。
  • 推荐涵盖抗炎、抗感染与支持治疗及随访。

研究设计与关键结果

  • 制定机构:瑞士儿科重症、免疫/风湿、感染、血液与心脏多学科临床专家;方法:文献回顾后四个工作组起草推荐,经改良Delphi流程,推荐须>80%同意方可接受。
  • 达成26条推荐,涵盖诊断方法、抗炎、抗感染与支持治疗及随访,并形成按表型(休克型、川崎病样型、未分化炎症型)指导治疗的管理算法。

证据类型、等级与局限

  • 证据类型:共识指南(最佳实践推荐),采用改良Delphi流程,推荐接受阈值>80%同意。
  • 证据基础:现有PIMS-TS文献仅限于回顾性或前瞻性观察性研究,并参考其他儿童与成人炎症性疾病的间接证据及国际卫生机构指南。
  • 局限:缺乏高级别证据,推荐需定期更新;原文未报告其他局限性。

对床旁实践的改变

  • 对疑似PIMS-TS患儿,可按管理算法依表型(休克、川崎病样、未分化炎症)分层决定治疗。
  • 推荐涵盖抗炎、抗感染、支持治疗及随访,可用于标准化瑞士疑似PIMS-TS患儿的治疗。
  • 作者认为鉴于缺乏高级别证据,推荐需定期更新,并鼓励患者参加试验。

指南或共识出处

  • 瑞士PIMS-TS最佳实践推荐(Front Pediatr),由瑞士多学科儿科临床专家组制定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of trials, evidence for treatment remains scarce. Purpose: To develop best practice recommendations for the diagnosis and treatment of children with PIMS-TS in Switzerland. It is acknowledged that the field is changing rapidly, and regular revisions in the coming months are pre-planned as evidence is increasing. Methods: Consensus guidelines for best practice were established by a multidisciplinary group of Swiss pediatric clinicians with expertise in intensive care, immunology/rheumatology, infectious diseases, hematology, and cardiology. Subsequent to literature review, four working groups established draft recommendations which were subsequently adapted in a modified Delphi process. Recommendations had to reach >80% agreement for acceptance. Results: The group achieved agreement on 26 recommendations, which specify diagnostic approaches and interventions across anti-inflammatory, anti-infectious, and support therapies, and follow-up for children with suspected PIMS-TS. A management algorithm was derived to guide treatment depending on the phenotype of presentation, categorized into PIMS-TS with (a) shock, (b) Kawasaki-disease like, and (c) undifferentiated inflammatory presentation. Conclusion: Available literature on PIMS-TS is limited to retrospective or prospective observational studies. Informed by these cohort studies and indirect evidence from other inflammatory conditions in children and adults, as well as guidelines from international health authorities, the Swiss PIMS-TS recommendations represent best practice guidelines based on currently available knowledge to standardize treatment of children with suspected PIMS-TS. Given the absence of high-grade evidence, regular updates of the recommendations will be warranted, and participation of patients in trials should be encouraged.

来源:Front Pediatr,查看原文。版权归原作者所有。

参考来源

  1. Schlapbach LJ, Andre MC, Grazioli S, et al. Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland. Front Pediatr. 2021. PMID: 34123970. doi:10.3389/fped.2021.667507

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。